A07EA04 betamethasone
ALIMENTARY TRACT AND METABOLISM ›ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS ›INTESTINAL ANTIINFLAMMATORY AGENTS ›Corticosteroids acting locally
非健保收載 TFDA 在效許可證 15 FDA 已核准
台灣藥品與外觀
無外觀照
貝皮質醇
無外觀照
"施可"貝他每松二丙鹽酸粉劑
資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。
適應症
台灣 TFDA 核准適應症
- 風濕性關節炎、支氣管氣喘、過敏性鼻炎、枯草熱、蕁麻疹、散佈性紅斑性狼瘡、濕疹、過敏性皮膚炎、休克及外科手術休克之防止、藥物中毒、風濕熱、強直性脊椎炎、痛風性關節炎。
- 濕疹、尿布疹、嬰兒濕疹、汗疹、手部濕疹、外耳炎、神經性皮膚炎、牛皮癬、皮脂溢出性皮膚炎、過敏性及接觸性皮膚炎。
- 濕疹、脂漏性皮膚炎、接觸性皮膚炎、異位性皮膚炎、神經性皮膚炎、過敏性皮膚炎、牛皮癬、紅皮症、灼傷、晒斑。
- 僂麻質性症狀、過敏性症狀、神經炎、濕疹、皮膚炎、乾癬、眼角膜炎、鼻炎、乾草熱、支氣管氣喘。
- 急慢性濕疹、接觸性皮膚炎、過敏性皮膚炎、神經性皮膚炎、異位性皮膚炎、牛皮癬、蕁麻疹、脂漏性皮膚炎。
- 風濕性關節炎、骨關節炎、支氣管氣喘、過敏性鼻炎、枯草熱、蕁麻疹、散佈性紅斑性狼瘡、過敏性皮膚炎。
- 風濕性關節炎、痛風性關節炎、支氣管氣喘、藥物過敏、枯草熱、濕疹、蕁痲疹、過敏性鼻炎。
- 風濕性關節炎、痛風性關節炎、支氣管氣喘、藥物過敏、枯草熱、濕疹、蕁麻疹、過敏性鼻炎。
- 急、慢性濕疹、乳小兒濕疹、貨幣狀濕疹、脂漏性濕疹、皮膚炎、蕁麻疹、乾癬。
- 僂麻質斯性及過敏性疾患、風濕性關節炎、支氣管氣喘、火傷大手術之應力狀態、肌無力、炎症性眼疾患。
- 僂麻質斯性及過敏性疾患:風濕性關節炎、支氣管氣喘、火傷、肌無力、炎症性眼疾患。
- 眼瞼炎、結膜炎、角膜炎、鞏膜炎、虹彩炎等之炎症性眼科疾患。
美國 FDA 適應症(英文原文對照)
INDICATIONS AND USAGE When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia).
資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。
健保給付規定
查無健保特殊給付規定條款;本藥品依一般健保藥品支付規定給付。
實證補充
本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。
台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-07-01)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。